Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction
详细信息 查看全文
- 作者：Leo Ungar (1)
Andre Altmann (1)
Michael D. Greicius (1) - 关键词：Alzheimer’s disease ; APOE ; Gender ; Genetics ; Aging and aging ; related diseases ; Neuroimaging
- 刊名：Brain Imaging and Behavior
- 出版年：2014
- 出版时间：June 2014
- 年：2014
- 卷：8
- 期：2
- 页码：262-273
- 全文大小：
- 参考文献：1. 2012 Alzheimer’s disease facts and figures. (2012). / Alzheimers Dement, / 8(2), 131-68. doi:10.1016/j.jalz.2012.02.001
2. Adamson, M. M., Hutchinson, J. B., Shelton, A. L., Wagner, A. D., & Taylor, J. L. (2011). Reduced hippocampal activity during encoding in cognitively normal adults carrying the APOE varepsilon4 allele. / Neuropsychologia, 49(9), 2448-455. doi:10.1016/j.neuropsychologia.2011.04.022 .
3. Aisen, P. S. (2011). Clinical trial methodologies for disease-modifying therapeutic approaches. / Neurobiology of Aging, 32(Suppl 1), S64–S66. doi:10.1016/j.neurobiolaging.2011.09.008 .
4. Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., & Tsopelas, N. D. (2008). Frequent amyloid deposition without significant cognitive impairment among the elderly. / Archives of Neurology, 65(11), 1509-517. doi:10.1001/archneur.65.11.1509 .
5. Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., & Fox, N. C. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. / Alzheimers Dement, 7(3), 270-79. doi:10.1016/j.jalz.2011.03.008 .
6. Altmann, A. A., Tian, L., Henderson, V. W., & Greicius, M. D. (2013). APOE genotype by gender interaction revealed in CSF biomarkers and clinical conversion rates in the ADNI database. / Alzheimer’s & Dementia: / The Journal of the Alzheimer’s Association, 9(4), 245-46.
7. Andrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., & Yoon, S. Y. (2010). Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. / Journal of Neuroscience, 30(41), 13707-3717. doi:10.1523/JNEUROSCI.4040-10.2010 .
8. Anstey, K., & Christensen, H. (2000). Education, activity, health, blood pressure and apolipoprotein E as predictors of cognitive change in old age: a review. / Gerontology, 46(3), 163-77.
9. Bai, F., Watson, D. R., Shi, Y., Wang, Y., Yue, C., & Teng, Y. (2011). Specifically progressive deficits of brain functional marker in amnestic type mild cognitive impairment. / PLoS One, 6(9), e24271. doi:10.1371/journal.pone.0024271 .
10. Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., & DeLong, C. (2009). Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. / Journal of Neuroscience, 29(21), 6771-779. doi:10.1523/JNEUROSCI.0887-09.2009 .
11. Bateman, R. J., Xiong, C., Benzinger, T. L., Fagan, A. M., Goate, A., & Fox, N. C. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. / New England Journal of Medicine, 367(9), 795-04. doi:10.1056/NEJMoa1202753 .
12. Beaudreau, S. A., Kaci Fairchild, J., Spira, A. P., Lazzeroni, L. C., & O’Hara, R. (2012). Neuropsychiatric symptoms, apolipoprotein E gene, and risk of progression to cognitive impairment, no dementia and dementia: the Aging, Demographics, and Memory Study (ADAMS). / International Journal of Geriatric Psychiatry. doi:10.1002/gps.3868 .
13. Bertram, L., Lill, C. M., & Tanzi, R. E. (2010). The genetics of Alzheimer disease: back to the future. / Neuron, 68(2), 270-81. doi:10.1016/j.neuron.2010.10.013 .
14. Bertram, L., & Tanzi, R. E. (2012). The genetics of Alzheimer’s disease. / Progress in Molecular Biology and Translational Science, 107, 79-00. doi:10.1016/B978-0-12-385883-2.00008-4 .
15. Beydoun, M. A., Boueiz, A., Abougergi, M. S., Kitner-Triolo, M. H., Beydoun, H. A., & Resnick, S. M. (2012). Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline. / Neurobiology of Aging, 33(4), 720-31. doi:10.1016/j.neurobiolaging.2010.05.017 . e724.
16. Blacker, D., Haines, J. L., Rodes, L., Terwedow, H., Go, R. C., & Harrell, L. E. (1997). ApoE-4 and age at onset of Alzheimer’s disease: the NIMH genetics initiative. / Neurology, 48(1), 139-47.
17. Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., et al. (2000). Patterns of brain activation in people at risk for Alzheimer’s disease. / New England Journal of Medicine, 343(7), 450-56.
18. Bour, A., Grootendorst, J., Vogel, E., Kelche, C., Dodart, J. C., & Bales, K. (2008). Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. / Behavioural Brain Research, 193(2), 174-82. doi:10.1016/j.bbr.2008.05.008 .
19. Brecht, W. J., Harris, F. M., Chang, S., Tesseur, I., Yu, G. Q., & Xu, Q. (2004). Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. / Journal of Neuroscience, 24(10), 2527-534. doi:10.1523/JNEUROSCI.4315-03.2004 .
20. Breitner, J. C., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C., & Norton, M. C. (1999). APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. / Neurology, 53(2), 321-31.
21. Bretsky, P. M., Buckwalter, J. G., Seeman, T. E., Miller, C. A., Poirier, J., & Schellenberg, G. D. (1999). Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. / Alzheimer Disease and Associated Disorders, 13(4), 216-21.
22. Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., & Ahern, G. L. (2009). Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. / New England Journal of Medicine, 361(3), 255-63. doi:10.1056/NEJMoa0809437 .
23. Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., & Patterson, B. W. (2011). Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. / Science Translational Medicine, 3(89), 89ra57. doi:10.1126/scitranslmed.3002156 .
24. Coker, L. H., Espeland, M. A., Rapp, S. R., Legault, C., Resnick, S. M., & Hogan, P. (2010). Postmenopausal hormone therapy and cognitive outcomes: the Women’s Health Initiative Memory Study (WHIMS). / Journal of Steroid Biochemistry and Molecular Biology, 118(4-), 304-10. doi:10.1016/j.jsbmb.2009.11.007 .
25. Corder, E. H., Ghebremedhin, E., Taylor, M. G., Thal, D. R., Ohm, T. G., & Braak, H. (2004). The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. / Annals of the New York Academy of Sciences, 1019, 24-8. doi:10.1196/annals.1297.005 .
26. Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., & Gaskell, P. C., Jr. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. / Nature Genetics, 7(2), 180-84.
27. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Jr., & Rimmler, J. B. (1995). Apolipoprotein E, survival in Alzheimer’s disease patients, and the competing risks of death and Alzheimer’s disease. / Neurology, 45(7), 1323-328.
28. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., & Small, G. W. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. / Science, 261(5123), 921-23.
29. Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., & McCormick, W. C. (1998). Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer’s disease. / Neurology, 51(1), 149-53.
30. Crivello, F., Lemaitre, H., Dufouil, C., Grassiot, B., Delcroix, N., & Tzourio-Mazoyer, N. (2010). Effects of ApoE-epsilon4 allele load and age on the rates of grey matter and hippocampal volumes loss in a longitudinal cohort of 1186 healthy elderly persons. / NeuroImage, 53(3), 1064-069. doi:10.1016/j.neuroimage.2009.12.116 .
31. Cummings, J. L. (2010). Integrating ADNI results into Alzheimer’s disease drug development programs. / Neurobiology of Aging, 31(8), 1481-492. doi:10.1016/j.neurobiolaging.2010.03.016 .
32. Dal Forno, G., Carson, K. A., Brookmeyer, R., Troncoso, J., Kawas, C. H., & Brandt, J. (2002). APOE genotype and survival in men and women with Alzheimer’s disease. / Neurology, 58(7), 1045-050.
33. Damoiseaux, J. S., Prater, K. E., Miller, B. L., & Greicius, M. D. (2012a). Functional connectivity tracks clinical deterioration in Alzheimer’s disease. / Neurobiology of Aging, 33(4), 828 e819-30. doi:10.1016/j.neurobiolaging.2011.06.024 .
34. Damoiseaux, J. S., Seeley, W. W., Zhou, J., Shirer, W. R., Coppola, G., & Karydas, A. (2012b). Gender modulates the APOE epsilon4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. / Journal of Neuroscience, 32(24), 8254-262. doi:10.1523/JNEUROSCI.0305-12.2012 .
35. den Heijer, T., Oudkerk, M., Launer, L. J., van Duijn, C. M., Hofman, A., & Breteler, M. M. (2002). Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. / Neurology, 59(5), 746-48.
36. Dennis, N. A., Browndyke, J. N., Stokes, J., Need, A., Burke, J. R., Welsh-Bohmer, K. A., et al. (2010). Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers. / Alzheimers Dement, 6(4), 303-11. doi:10.1016/j.jalz.2009.07.003 .
37. Devanand, D. P., Pelton, G. H., Zamora, D., Liu, X., Tabert, M. H., & Goodkind, M. (2005). Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. / Archives of Neurology, 62(6), 975-80. doi:10.1001/archneur.62.6.975 .
38. Dickson, M. R., Li, J., Wiener, H. W., Perry, R. T., Blacker, D., Bassett, S. S., et al. (2008). A genomic scan for age at onset of Alzheimer’s disease in 437 families from the NIMH Genetic Initiative. / American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B(6), 784-92. doi:10.1002/ajmg.b.30689 .
39. Drago, V., Babiloni, C., Bartres-Faz, D., Caroli, A., Bosch, B., & Hensch, T. (2011). Disease tracking markers for Alzheimer’s disease at the prodromal (MCI) stage. / Journal of Alzheimer’s Disease, 26(Suppl 3), 159-99. doi:10.3233/JAD-2011-0043 .
40. Drzezga, A., Grimmer, T., Henriksen, G., Muhlau, M., Perneczky, R., & Miederer, I. (2009). Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. / Neurology, 72(17), 1487-494. doi:10.1212/WNL.0b013e3181a2e8d0 .
41. Du, A. T., Schuff, N., Chao, L. L., Kornak, J., Jagust, W. J., & Kramer, J. H. (2006). Age effects on atrophy rates of entorhinal cortex and hippocampus. / Neurobiology of Aging, 27(5), 733-40. doi:10.1016/j.neurobiolaging.2005.03.021 .
42. Dumanis, S. B., Tesoriero, J. A., Babus, L. W., Nguyen, M. T., Trotter, J. H., & Ladu, M. J. (2009). ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. / Journal of Neuroscience, 29(48), 15317-5322. doi:10.1523/JNEUROSCI.4026-09.2009 .
43. Farlow, M. R. (2010). Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? / Alzheimer’s Research & Therapy, 2(3), 15. doi:10.1186/alzrt39 .
44. Farlow, M. R., Lahiri, D. K., Poirier, J., Davignon, J., Schneider, L., & Hui, S. L. (1998). Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer’s disease. / Neurology, 50(3), 669-77.
45. Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., & Mayeux, R. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. / JAMA, 278(16), 1349-356.
46. Filippini, N., Ebmeier, K. P., MacIntosh, B. J., Trachtenberg, A. J., Frisoni, G. B., & Wilcock, G. K. (2011). Differential effects of the APOE genotype on brain function across the lifespan. / NeuroImage, 54(1), 602-10. doi:10.1016/j.neuroimage.2010.08.009 .
47. Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., & Smith, S. M. (2009). Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. / Proceedings of the National Academy of Sciences of the United States of America, 106(17), 7209-214.
48. Fleisher, A., Grundman, M., Jack, C. R., Jr., Petersen, R. C., Taylor, C., & Kim, H. T. (2005). Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. / Archives of Neurology, 62(6), 953-57. doi:10.1001/archneur.62.6.953 .
49. Ghebremedhin, E., Schultz, C., Thal, D. R., Rub, U., Ohm, T. G., Braak, E., et al. (2001). Gender and age modify the association between APOE and AD-related neuropathology. / Neurology, 56(12), 1696-701.
50. Goldman, J. S., Hahn, S. E., Catania, J. W., LaRusse-Eckert, S., Butson, M. B., & Rumbaugh, M. (2011). Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. / Genetics in Medicine, 13(6), 597-05. doi:10.1097/GIM.0b013e31821d69b8 .
51. Gomez-Tortosa, E., Barquero, M. S., Baron, M., Sainz, M. J., Manzano, S., & Payno, M. (2007). Variability of age at onset in siblings with familial Alzheimer disease. / Archives of Neurology, 64(12), 1743-748. doi:10.1001/archneur.64.12.1743 .
52. Greicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004). Default-mode network activity distinguishes Alzheimer’s disease from healthy aging: evidence from functional MRI. / Proceedings of the National Academy of Sciences of the United States of America, 101(13), 4637-642.
53. Guerreiro, R. J., & Hardy, J. (2011). Alzheimer’s disease genetics: lessons to improve disease modelling. / Biochemical Society Transactions, 39(4), 910-16. doi:10.1042/BST0390910 .
54. Henderson, V. W. (2009). Aging, estrogens, and episodic memory in women. / Cognitive and Behavioral Neurology, 22(4), 205-14. doi:10.1097/WNN.0b013e3181a74ce7 .
55. Hirono, N., Hashimoto, M., Yasuda, M., Kazui, H., & Mori, E. (2003). Accelerated memory decline in Alzheimer’s disease with apolipoprotein epsilon4 allele. / Journal of Neuropsychiatry and Clinical Neurosciences, 15(3), 354-58.
56. Huang, Y. (2010). Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer’s disease. / Trends in Molecular Medicine, 16(6), 287-94. doi:10.1016/j.molmed.2010.04.004 .
57. Jack, C. R., Jr. (2012). Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. / Radiology, 263(2), 344-61. doi:10.1148/radiol.12110433 .
58. Jack, C. R., Jr., Bernstein, M. A., Borowski, B. J., Gunter, J. L., Fox, N. C., & Thompson, P. M. (2010). Update on the magnetic resonance imaging core of the Alzheimer’s disease neuroimaging initiative. / Alzheimers Dement, 6(3), 212-20. doi:10.1016/j.jalz.2010.03.004 .
59. Jak, A. J., Houston, W. S., Nagel, B. J., Corey-Bloom, J., & Bondi, M. W. (2007). Differential cross-sectional and longitudinal impact of APOE genotype on hippocampal volumes in nondemented older adults. / Dementia and Geriatric Cognitive Disorders, 23(6), 382-89. doi:10.1159/000101340 .
60. Jorm, A. F., Mather, K. A., Butterworth, P., Anstey, K. J., Christensen, H., & Easteal, S. (2007). APOE genotype and cognitive functioning in a large age-stratified population sample. / Neuropsychology, 21(1), 1-. doi:10.1037/0894-4105.21.1.1 .
61. Kang, J. H., & Grodstein, F. (2012). Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. / Neurobiology of Aging, 33(7), 1129-137. doi:10.1016/j.neurobiolaging.2010.10.007 .
62. Khachaturian, A. S., Corcoran, C. D., Mayer, L. S., Zandi, P. P., & Breitner, J. C. (2004). Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. / Archives of General Psychiatry, 61(5), 518-24. doi:10.1001/archpsyc.61.5.518 .
63. Kleiman, T., Zdanys, K., Black, B., Rightmer, T., Grey, M., & Garman, K. (2006). Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer’s disease: retrospective and prospective analysis. / Dementia and Geriatric Cognitive Disorders, 22(1), 73-2. doi:10.1159/000093316 .
64. Kukolja, J., Thiel, C. M., Eggermann, T., Zerres, K., & Fink, G. R. (2010). Medial temporal lobe dysfunction during encoding and retrieval of episodic memory in non-demented APOE epsilon4 carriers. / Neuroscience, 168(2), 487-97. doi:10.1016/j.neuroscience.2010.03.044 .
65. Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., & Aisen, P. S. (2010). Comparing predictors of conversion and decline in mild cognitive impairment. / Neurology, 75(3), 230-38. doi:10.1212/WNL.0b013e3181e8e8b8 .
66. Lehmann, D. J., Refsum, H., Nurk, E., Warden, D. R., Tell, G. S., & Vollset, S. E. (2006). Apolipoprotein E epsilon4 and impaired episodic memory in community-dwelling elderly people: a marked sex difference. The Hordaland Health Study. / Journal of Neurology, Neurosurgery and Psychiatry, 77(8), 902-08. doi:10.1136/jnnp.2005.077818 .
67. Lemaitre, H., Crivello, F., Dufouil, C., Grassiot, B., Tzourio, C., Alperovitch, A., et al. (2005). No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. / NeuroImage, 24(4), 1205-213. doi:10.1016/j.neuroimage.2004.10.016 .
68. Lu, P. H., Thompson, P. M., Leow, A., Lee, G. J., Lee, A., & Yanovsky, I. (2011). Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study. / Journal of Alzheimer’s Disease, 23(3), 433-42. doi:10.3233/JAD-2010-101398 .
69. MacGowan, S. H., Wilcock, G. K., & Scott, M. (1998). Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer’s disease. / International Journal of Geriatric Psychiatry, 13(9), 625-30.
70. Machulda, M. M., Jones, D. T., Vemuri, P., McDade, E., Avula, R., & Przybelski, S. (2011). Effect of APOE epsilon4 status on intrinsic network connectivity in cognitively normal elderly subjects. / Archives of Neurology, 68(9), 1131-136. doi:10.1001/archneurol.2011.108 .
71. Mayeux, R., Small, S. A., Tang, M., Tycko, B., & Stern, Y. (2001). Memory performance in healthy elderly without Alzheimer’s disease: effects of time and apolipoprotein-E. / Neurobiology of Aging, 22(4), 683-89.
72. McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Jr., & Kawas, C. H. (2011). The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. / Alzheimers Dement, 7(3), 263-69. doi:10.1016/j.jalz.2011.03.005 .
73. Messner, D. A. (2011). Informed Choice in Direct-to-Consumer Genetic Testing for Alzheimer and Other Diseases: Lessons from Two Cases. / New Genetics and Society, 30(1), 59-2. doi:10.1080/14636778.2011.552300 .
74. Meyer-Lindenberg, A., & Weinberger, D. R. (2006). Intermediate phenotypes and genetic mechanisms of psychiatric disorders. / Nature Review Neuroscience, 7(10), 818-27.
75. Moffat, S. D., Szekely, C. A., Zonderman, A. B., Kabani, N. J., & Resnick, S. M. (2000). Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype. / Neurology, 55(1), 134-36.
76. Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., et al. (2010). APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. / Annals of Neurology, 67(1), 122-31. doi:10.1002/ana.21843 .
77. Mortensen, E. L., & Hogh, P. (2001). A gender difference in the association between APOE genotype and age-related cognitive decline. / Neurology, 57(1), 89-5.
78. Nyholt, D. R., Yu, C.-E., & Visscher, P. M. (2008). On Jim Watson’s APOE status: genetic information is hard to hide. / European Journal of Human Genetics, 17(2), 147-49.
79. Payami, H., Montee, K. R., Kaye, J. A., Bird, T. D., Yu, C. E., Wijsman, E. M., et al. (1994). Alzheimer’s disease, apolipoprotein E4, and gender. / JAMA, 271(17), 1316-317.
80. Payami, H., Zareparsi, S., Montee, K. R., Sexton, G. J., Kaye, J. A., & Bird, T. D. (1996). Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. / American Journal of Human Genetics, 58(4), 803-11.
81. Peskind, E. R., Li, G., Shofer, J., Quinn, J. F., Kaye, J. A., & Clark, C. M. (2006). Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. / Archives of Neurology, 63(7), 936-39. doi:10.1001/archneur.63.7.936 .
82. Petersen, R. C., Smith, G. E., Ivnik, R. J., Tangalos, E. G., Schaid, D. J., & Thibodeau, S. N. (1995). Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. / JAMA, 273(16), 1274-278.
83. Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., & Ferris, S. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. / New England Journal of Medicine, 352(23), 2379-388. doi:10.1056/NEJMoa050151 .
84. Raber, J., Bongers, G., LeFevour, A., Buttini, M., & Mucke, L. (2002). Androgens protect against apolipoprotein E4-induced cognitive deficits. / Journal of Neuroscience, 22(12), 5204-209.
85. Raber, J., Wong, D., Buttini, M., Orth, M., Bellosta, S., & Pitas, R. E. (1998). Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. / Proceedings of the National Academy of Sciences of the United States of America, 95(18), 10914-0919.
86. Raber, J., Wong, D., Yu, G. Q., Buttini, M., Mahley, R. W., Pitas, R. E., et al. (2000). Apolipoprotein E and cognitive performance. / Nature, 404(6776), 352-54. doi:10.1038/35006165 .
87. Raskind, M. A., Peskind, E. R., Wessel, T., & Yuan, W. (2000). Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. / Neurology, 54(12), 2261-268.
88. Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001). Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. / Proceedings of the National Academy of Sciences of the United States of America, 98(6), 3334-339.
89. Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., & Minoshima, S. (1996). Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. / New England Journal of Medicine, 334(12), 752-58.
90. Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., & Osborne, D. (2004). Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. / Proceedings of the National Academy of Sciences of the United States of America, 101(1), 284-89. doi:10.1073/pnas.2635903100 .
91. Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., & Lee, W. (2009). Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. / Proceedings of the National Academy of Sciences of the United States of America, 106(16), 6820-825. doi:10.1073/pnas.0900345106 .
92. Reiman, E. M., Langbaum, J. B., Fleisher, A. S., Caselli, R. J., Chen, K., & Ayutyanont, N. (2011). Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. / Journal of Alzheimer’s Disease, 26(Suppl 3), 321-29. doi:10.3233/JAD-2011-0059 .
93. Reiman, E. M., Uecker, A., Caselli, R. J., Lewis, S., Bandy, D., & de Leon, M. J. (1998). Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer’s disease. / Annals of Neurology, 44(2), 288-91. doi:10.1002/ana.410440226 .
94. Reinvang, I., Winjevoll, I. L., Rootwelt, H., & Espeseth, T. (2010). Working memory deficits in healthy APOE epsilon 4 carriers. / Neuropsychologia, 48(2), 566-73. doi:10.1016/j.neuropsychologia.2009.10.018 .
95. Reverte, I., Klein, A. B., Ratner, C., Domingo, J. L., & Colomina, M. T. (2012). Behavioral phenotype and BDNF differences related to apoE isoforms and sex in young transgenic mice. / Experimental Neurology, 237(1), 116-25. doi:10.1016/j.expneurol.2012.06.015 .
96. Rigaud, A.-S., Traykov, L., Latour, F., Couderc, R., Moulin, F., & Forette, F. (2002). Presence or absence of at least one [small element of]4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer’s disease. / Pharmacogenetics and Genomics, 12(5), 415-20.
97. Rijpma, A., Jansen, D., Arnoldussen, I. A. C., Fang, X. T., Wiesmann, M., & Mutsaers, M. P. C. (2013). Sex Differences in Presynaptic Density and Neurogenesis in Middle-Aged ApoE4 and ApoE Knockout Mice. / Journal of Neurodegenerative Diseases, 2013, 9. doi:10.1155/2013/531326 .
98. Risner, M. E., Saunders, A. M., Altman, J. F., Ormandy, G. C., Craft, S., & Foley, I. M. (2006). Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. / Pharmacogenomics Journal, 6(4), 246-54. doi:10.1038/sj.tpj.6500369 .
99. Rodrigue, K. M., Kennedy, K. M., Devous, M. D., Sr., Rieck, J. R., Hebrank, A. C., & Diaz-Arrastia, R. (2012). beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. / Neurology, 78(6), 387-95. doi:10.1212/WNL.0b013e318245d295 .
100. Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., & Friedhoff, L. T. (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. / Neurology, 50(1), 136-45.
101. Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., & Dal-Bianco, P. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. / BMJ, 318(7184), 633-38.
102. Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., & Raskind, M. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. / Neurology, 73(24), 2061-070. doi:10.1212/WNL.0b013e3181c67808 .
103. Samuraki, M., Matsunari, I., Chen, W. P., Shima, K., Yanase, D., & Takeda, N. (2012). Glucose metabolism and gray-matter concentration in apolipoprotein E epsilon4 positive normal subjects. / Neurobiology of Aging, 33(10), 2321-323. doi:10.1016/j.neurobiolaging.2011.11.020 .
104. Saunders, A. M., Strittmatter, W. J., Schmechel, D., George-Hyslop, P. H., Pericak-Vance, M. A., & Joo, S. H. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. / Neurology, 43(8), 1467-472.
105. Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P. S., & Petersen, R. C. (2009). Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. / Annals of Neurology, 65(4), 403-13. doi:10.1002/ana.21610 .
106. Sheline, Y. I., Morris, J. C., Snyder, A. Z., Price, J. L., Yan, Z., & D’Angelo, G. (2010). APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. / Journal of Neuroscience, 30(50), 17035-7040. doi:10.1523/JNEUROSCI.3987-10.2010 .
107. Sloane, P. D., Zimmerman, S., Suchindran, C., Reed, P., Wang, L., Boustani, M., et al. (2002). The public health impact of Alzheimer’s disease, 2000-050: potential implication of treatment advances. / Annual Review of Public Health, 23, 213-31.
108. Slooter, A. J., Houwing-Duistermaat, J. J., van Harskamp, F., Cruts, M., Van Broeckhoven, C., & Breteler, M. M. (1999). Apolipoprotein E genotype and progression of Alzheimer’s disease: the Rotterdam Study. / Journal of Neurology, 246(4), 304-08.
109. Small, G. W., Ercoli, L. M., Silverman, D. H., Huang, S. C., Komo, S., & Bookheimer, S. Y. (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. / Proceedings of the National Academy of Sciences of the United States of America, 97(11), 6037-042.
110. Small, G. W., Mazziotta, J. C., Collins, M. T., Baxter, L. R., Phelps, M. E., & Mandelkern, M. A. (1995). Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. / JAMA, 273(12), 942-47.
111. Sorg, C., Riedl, V., Muhlau, M., Calhoun, V. D., Eichele, T., & Laer, L. (2007). Selective changes of resting-state networks in individuals at risk for Alzheimer’s disease. / Proceedings of the National Academy of Sciences of the United States of America, 104(47), 18760-8765.
112. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., & Fagan, A. M. (2011). Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. / Alzheimers Dement, 7(3), 280-92. doi:10.1016/j.jalz.2011.03.003 .
113. Stern, Y., Brandt, J., Albert, M., Jacobs, D. M., Liu, X., & Bell, K. (1997). The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer’s disease. / Annals of Neurology, 41(5), 615-20. doi:10.1002/ana.410410510 .
114. Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., et al. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. / Proceedings of the National Academy of Sciences of the United States of America, 90(5), 1977-981.
115. Sunderland, T., Mirza, N., Putnam, K. T., Linker, G., Bhupali, D., & Durham, R. (2004). Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer’s disease: the effect of APOE epsilon4 allele. / Biological Psychiatry, 56(9), 670-76. doi:10.1016/j.biopsych.2004.07.021 .
116. Swan, G. E., Lessov-Schlaggar, C. N., Carmelli, D., Schellenberg, G. D., & La Rue, A. (2005). Apolipoprotein E epsilon4 and change in cognitive functioning in community-dwelling older adults. / Journal of Geriatric Psychiatry and Neurology, 18(4), 196-01. doi:10.1177/0891988705281864 .
117. Talbot, C., Lendon, C., Craddock, N., Shears, S., Morris, J. C., & Goate, A. (1994). Protection against Alzheimer’s disease with apoE epsilon 2. / Lancet, 343(8910), 1432-433.
118. Tierney, M. C., Szalai, J. P., Snow, W. G., Fisher, R. H., Tsuda, T., & Chi, H. (1996). A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. / Neurology, 46(1), 149-54.
119. Tilvis, R. S., Strandberg, T. E., & Juva, K. (1998). Apolipoprotein E phenotypes, dementia and mortality in a prospective population sample. / Journal of American Geriatrics Society, 46(6), 712-15.
120. Tohgi, H., Takahashi, S., Kato, E., Homma, A., Niina, R., & Sasaki, K. (1997). Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E epsilon4 allele. / Neuroscience Letters, 236(1), 21-4.
121. Trachtenberg, A. J., Filippini, N., Ebmeier, K. P., Smith, S. M., Karpe, F., & Mackay, C. E. (2012). The effects of APOE on the functional architecture of the resting brain. / NeuroImage, 59(1), 565-72. doi:10.1016/j.neuroimage.2011.07.059 .
122. Trojanowski, J. Q., Vandeerstichele, H., Korecka, M., Clark, C. M., Aisen, P. S., & Petersen, R. C. (2010). Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. / Alzheimers Dement, 6(3), 230-38. doi:10.1016/j.jalz.2010.03.008 .
123. Tupler, L. A., Krishnan, K. R., Greenberg, D. L., Marcovina, S. M., Payne, M. E., & MacFall, J. R. (2007). Predicting memory decline in normal elderly: genetics, MRI, and cognitive reserve. / Neurobiology of Aging, 28(11), 1644-656. doi:10.1016/j.neurobiolaging.2006.07.001 .
124. van Duijn, C. M., de Knijff, P., Wehnert, A., De Voecht, J., Bronzova, J. B., & Havekes, L. M. (1995). The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer’s disease and a reduced survival. / Annals of Neurology, 37(5), 605-10. doi:10.1002/ana.410370510 .
125. Van Gerven, P. W., Van Boxtel, M. P., Ausems, E. E., Bekers, O., & Jolles, J. (2012). Do apolipoprotein E genotype and educational attainment predict the rate of cognitive decline in normal aging? A 12-year follow-up of the Maastricht Aging Study. / Neuropsychology, 26(4), 459-72. doi:10.1037/a0028685 .
126. van Meer, P., Acevedo, S., & Raber, J. (2007). Impairments in spatial memory retention of GFAP-apoE4 female mice. / Behavioural Brain Research, 176(2), 372-75. doi:10.1016/j.bbr.2006.10.024 .
127. Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Trojanowski, J. Q., & Shaw, L. M. (2010). Serial MRI and CSF biomarkers in normal aging, MCI, and AD. / Neurology, 75(2), 143-51. doi:10.1212/WNL.0b013e3181e7ca82 .
128. Wang, K., Liang, M., Wang, L., Tian, L., Zhang, X., Li, K., et al. (2007). Altered functional connectivity in early Alzheimer’s disease: a resting-state fMRI study. / Human Brain Mapping, 28(10), 967-78. doi:10.1002/hbm.20324 .
129. Wang, P. N., Hong, C. J., Lin, K. N., Liu, H. C., & Chen, W. T. (2011). APOE epsilon4 increases the risk of progression from amnestic mild cognitive impairment to Alzheimer’s disease among ethnic Chinese in Taiwan. / Journal of Neurology, Neurosurgery and Psychiatry, 82(2), 165-69. doi:10.1136/jnnp.2010.209122 .
130. Ward, A., Crean, S., Mercaldi, C. J., Collins, J. M., Boyd, D., Cook, M. N., et al. (2012). Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: a systematic review and meta-analysis. / Neuroepidemiology, 38(1), 1-7. doi:10.1159/000334607 .
131. Westlye, E. T., Lundervold, A., Rootwelt, H., Lundervold, A. J., & Westlye, L. T. (2011). Increased hippocampal default mode synchronization during rest in middle-aged and elderly APOE epsilon4 carriers: relationships with memory performance. / Journal of Neuroscience, 31(21), 7775-783. doi:10.1523/JNEUROSCI.1230-11.2011 .
132. Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000). Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. / BMJ, 321(7274), 1445-449.
133. Yaffe, K., Haan, M., Byers, A., Tangen, C., & Kuller, L. (2000). Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. / Neurology, 54(10), 1949-954.
134. Zhang, H. Y., Wang, S. J., Xing, J., Liu, B., Ma, Z. L., & Yang, M. (2009). Detection of PCC functional connectivity characteristics in resting-state fMRI in mild Alzheimer’s disease. / Behavioural Brain Research, 197(1), 103-08.
135. Zhong, N., & Weisgraber, K. H. (2009). Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. / Journal of Biological Chemistry, 284(10), 6027-031. doi:10.1074/jbc.R800009200 . - 作者单位：Leo Ungar (1)
Andre Altmann (1)
Michael D. Greicius (1)
1. Functional Imaging in Neuropsychiatric Disorders (FIND) Lab, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA - ISSN：1931-7565
文摘
Alzheimer’s disease (AD) is an increasingly prevalent, fatal neurodegenerative disease that has proven resistant, thus far, to all attempts to prevent it, forestall it, or slow its progression. The ε4 allele of the Apolipoprotein E gene (APOE4) is a potent genetic risk factor for sporadic and late-onset familial AD. While the link between APOE4 and AD is strong, many expected effects, like increasing the risk of conversion from MCI to AD, have not been widely replicable. One critical, and commonly overlooked, feature of the APOE4 link to AD is that several lines of evidence suggest it is far more pronounced in women than in men. Here we review previous literature on the APOE4 by gender interaction with a particular focus on imaging-related studies.